Sign in
WithdrawnPhase 3

Macitentan to Prevent PRVO

Key facts

Who runs it
University of Maryland, Baltimore
Where
Baltimore, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 3
Started
1 May 2024
Expected to end
1 Jun 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Macitentan 10mg
Record updated
8 March 2024
Why it stopped
Study was cancelled by funding agency before starting enrollment.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (18)Hide the full registry criteria

Who can take part

  • Age 18-75 years old
  • Acute high-risk or intermediate-risk PE diagnosed by CTPA within 28 days prior to enrollment

Who cannot take part

  • Surgical interventions to treat PE including catheter-directed thrombolysis, catheter-based thrombectomy, or surgical pulmonary embolectomy
  • History of pulmonary embolism prior to index PE
  • Current or previous use within 90 days of an endothelin-receptor antagonist, prostacyclin analogue, phosphodiesterase type 5 inhibitor, or nitric oxide donor
  • Subjects receiving CYP3A4 and CYP2C9 inhibitors or inducers such as rifampin, ritonavir, fluconazole, amiodarone
  • Allergy or contraindications to Macitentan or any other endothelin receptor antagonist
  • History of pulmonary hypertension including Group 1 (Primary pulmonary hypertension), Group 2 (secondary to left heart disease), Group 3 (secondary to lung disease), Group 4 (Chronic thromboembolic pulmonary hypertension)
  • Severe chronic obstructive pulmonary disease
  • History of radiation therapy to the chest
  • Severe allergic reaction to iodine contrast
  • Contraindication for anticoagulation
  • Known inherited or acquired hypercoagulable states
  • Severe uncontrolled asthma
  • Pregnancy or fertility treatment
  • Breastfeeding
  • Life expectancy is less than 6 months
  • Not able to read or understand the English language

Where in United States

  • University of Maryland Medical CenterBaltimore, United States

About the trial

What the trial wants to find out

About half of patients who suffer of a pulmonary embolism (blood clots in the lungs), do not clear completely the clots overtime, increasing the risk of having a new blood clot in the lungs and elevated blood pressure in the pulmonary artery; therefore, developing fatigue, shortness of breath, and heart failure.

Read full original descriptionShow less

The objective of this clinical trial is to compare 3 months of daily Macitentan (a medicine to increase the diameter of the pulmonary artery) in addition to blood thinners vs. blood thinners alone in patients with acute blood clots in the pulmonary artery:

Question 1: Whether the use of Macitentan in addition to blood thinners enhances the process of cleaning the blood clot in the pulmonary artery compared to blood thinners alone.

Question 2: Whether the use of Macitentan in addition to blood thinners is associated to improve the fatigue and shortness of breath in patients after a pulmonary embolism compared to blood thinners alone.

Participants will be asked to take a capsule for 3 months in addition to blood thinners. The capsule could contain either Macitentan (medicine) or a placebo (not medicine). In 3 months, participants will have a new image of the pulmonary artery to document the cleaning of the clots. Also, blood and urine samples will be collected, as well as a questionnaire will be filled out. In 6 months, patients will have repeated images of the heart as well as repeated questionnaires.

The 2 groups in the trial

  • Macitentan armTreatment being tested

    Participants allocated to this arm will receive Macitentan 10 mg daily for 3 months

    Treatment: Macitentan 10mg

  • PlaceboPlacebo, for comparison

    Participants allocated to this arm will receive placebo daily for 3 months.

    Treatment: Macitentan 10mg

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Role of MACitentan on the Prevention of Residual Pulmonary vasculaR Occlusion
Record updated
8 March 2024